15 Supported by research
Richard Nixon's Controlled Substances Act of 1970 virtually shut down research on psychedelic therapies.
"It dates back to Richard Nixon's Controlled Substances Act of 1970 that virtually shut down research on psychedelic therapies. It was a very fertile and vibrant field in the 1960s before the kibosh came down." (said at 0:05:36)
The speaker's statement accurately reflects the historical record and scientific consensus. Following extensive clinical experimentation and psychiatric research in the 1950s and 1960s, the passage of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Controlled Substances Act) under the Nixon administration placed classical psychedelics (including LSD, psilocybin, and mescaline) into Schedule I. This regulatory classification categorized them as having high abuse potential and no accepted medical use, effectively halting clinical trials and development of psychedelic therapies in the United States for several decades until research resumed in the late 1990s and 2000s.
In a phase two study of MDMA-assisted therapy for severe PTSD, approximately two-thirds of participants no longer met diagnostic criteria for PTSD at the primary endpoint and at one-year follow-up.
"and I was the study physician and one of the MDMA therapists on a phase two study that led to the breakthrough designation and on into phase three. And by the time we were done with this phase two study, where, by the way, about two-thirds of the folks with very severe PTSD no longer met criteria anymore at the primary endpoint, and still were not meeting criteria at the one-year follow-up." (said at 0:07:10)
The speaker's statement accurately reflects the published findings from the pooled Phase 2 clinical trial program that supported the FDA's Breakthrough Therapy designation for MDMA-assisted psychotherapy. In the pooled Phase 2 data, 54.2% to 56.0% of participants no longer met PTSD diagnostic criteria at the post-treatment endpoint, and this proportion increased to 67.0% (approximately two-thirds) at the long-term follow-up (≥12 months). It should be noted that in 2024, the journal retracted these pooled analysis papers due to ethical violations and protocol non-compliance identified at one of the participating study sites, though the historical reported numbers match the claim.
The FDA initially denied approval for MDMA-assisted therapy in the summer of 2024.
"The MDMA phase three study is complete. FDA initially denied approval last summer in 2024." (said at 0:08:30)
The speaker's statement is accurate. In August 2024 (the summer of 2024), the US Food and Drug Administration (FDA) reviewed the new drug application submitted by Lykos Therapeutics for MDMA-assisted psychotherapy for post-traumatic stress disorder (following completed Phase 3 trials) and issued a Complete Response Letter declining approval, requesting an additional Phase 3 trial to address concerns regarding study design, functional unblinding, safety assessments, and trial conduct.
Ketamine is classified as a DEA Schedule III drug in the United States, while psilocybin and MDMA are Schedule I.
"And of course, ketamine-assisted therapy is widely available on DEA schedule three. So, for the time being, psilocybin and MDMA are still on schedule one." (said at 0:08:55)
The speaker's statement accurately reflects United States federal drug scheduling under the Controlled Substances Act administered by the DEA. Psilocybin and MDMA are classified as Schedule I controlled substances, a legal designation that has historically restricted clinical research. In contrast, ketamine is a DEA Schedule III controlled substance, allowing it to be legally prescribed and administered off-label or on-label (e.g., esketamine) in medical and therapeutic settings.
- supports: Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overv… (American journal of therapeutics ) · cited 12x in the literature
"Because of the decades-long status of several psychedelics as Schedule I drugs, there have not been very many large, double-blind, randomized controlled trials of psychedelics." (abstract, passage verified)
pubmedfull study (doi) - supports: Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations. (Expert opinion on pharmacotherapy 2026)
"Particular attention will be given to regulatory pathways, scheduling constraints, access mechanisms, and compound-specific approval trajectories in the United States, European Union, and selected international jurisdictions." (abstract, passage verified)
pubmedfull study (doi)
Ibogaine causes cardiac toxicity.
"Well, ibogaine in particular has this cardiac toxicity that we have to be very, very careful about." (said at 0:17:26)
Published clinical and toxicological literature well establishes that ibogaine carries a significant risk of cardiac toxicity. Mechanistically, ibogaine and its active metabolite noribogaine block human ether-à-go-go-related gene (hERG) potassium channels, delaying cardiac repolarization and prolonging the QTc interval. This prolongation significantly elevates the risk of life-threatening ventricular arrhythmias, including Torsades de Pointes and sudden cardiac arrest, even at therapeutic doses and in patients without pre-existing cardiac disease. Consequently, comprehensive cardiovascular monitoring and screening are standard precautions in clinical research evaluating ibogaine.
A Stanford University study evaluating ibogaine treatment in Navy SEALs in Mexico combined magnesium with ibogaine alongside cardiac monitoring throughout dosing to mitigate cardiac risk.
"And you know, the recent work with Navy SEALs in Mexico that was published out of Stanford University combined magnesium with ibogaine and cardiac monitoring throughout the dosing experience, and I think there are ways to mitigate risk." (said at 0:17:35)
A prospective observational study published by researchers at Stanford University (Williams et al., Nature Medicine 2024) evaluated the 'Magnesium-Ibogaine: the Stanford Traumatic Injury to the CNS' (MISTIC) protocol in 30 male Special Operations Forces veterans treated at a clinic in Mexico. The protocol co-administered oral and intravenous magnesium with ibogaine and implemented continuous cardiac monitoring to mitigate the risk of QTc prolongation and fatal cardiac arrhythmias associated with ibogaine.
Serious neuroscientists do not agree with or support the serotonin deficiency model of depression.
"Well if you ask any serious neuroscientist whether they believe in a serotonin deficiency model of depression, nobody will agree with you. You can't find one because it doesn't make sense. It's a marketing strategy." (said at 0:31:10)
Contemporary neuroscience and psychiatric research widely reject the simplistic 'serotonin deficiency' or 'chemical imbalance' model of depression. A landmark 2023 systematic umbrella review by Moncrieff et al. evaluated decades of evidence across multiple research streams (metabolite levels, receptor binding, transporter availability, tryptophan depletion, and genetics) and found no consistent evidence that depression is caused by lowered serotonin concentration or activity. In response to this review, psychiatric researchers noted that the original monoamine/serotonin deficiency hypothesis has been considered outdated across neurobiology for decades, acknowledging that depression involves complex, heterogeneous neurobiological networks rather than a simple deficit of a single neurotransmitter. Analyses have also highlighted the disconnect between direct-to-consumer pharmaceutical advertising—which popularized the chemical imbalance framing—and the underlying scientific literature.
Quinolinic acid exerts excitotoxic effects at the NMDA receptor.
"It turns out that quinolinic acid is excitotoxic at the NMDA receptor." (said at 0:37:28)
Quinolinic acid is an endogenous metabolite of the kynurenine pathway that acts as an agonist at NMDA (N-methyl-D-aspartate) glutamate receptors. Its overactivation of NMDA receptors leads to excessive intracellular calcium influx and neuronal excitotoxicity.
A study found that suicide attempters had up to 300% elevated levels of quinolinic acid in their cerebrospinal fluid.
"It also turns out that people who attempt suicide have in one study up to 300% elevated levels of quinolinic acid in their CSF." (said at 0:37:33)
A clinical study by Erhardt et al. (2013) evaluated cerebrospinal fluid (CSF) metabolites in 64 medication-free suicide attempters compared to 36 healthy controls and found markedly elevated CSF levels of quinolinic acid (QUIN) (P < 0.001), with levels correlating positively with scores on the Suicide Intent Scale and CSF interleukin-6. Follow-up research by the same team confirmed sustained dysregulation of quinolinic acid in suicide attempters. Because the evidence is derived from observational case-control studies, the certainty of the body of evidence is low.
- supports: Connecting inflammation with glutamate agonism in suicidality. (Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013) · cited 344x in the literature
"We found that QUIN, but not KYNA, was significantly elevated in the CSF of suicide attempters (P<0.001). As predicted, the increase in QUIN was associated with higher levels of CSF interleukin-6. Moreover, QUIN levels correlated with the total scores on Suicide Intent Scale." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate re… (Brain, behavior, and immunity 2015) · cited 300x in the literature
"Quinolinic acid was increased and kynurenic acid decreased over time in suicidal patients versus healthy controls." (abstract, results, passage verified)
pubmedfull study (doi)
Ketamine administration frequently resolves suicidal ideation within the first few hours.
"And often times with ketamine in the first few hours you'll see suicidal thinking go away. It's quite remarkable. It's almost like a magic trick." (said at 0:37:50)
Multiple systematic reviews and meta-analyses of randomized controlled trials confirm that sub-anesthetic doses of intravenous ketamine rapidly and significantly reduce or resolve suicidal ideation within the first 4 to 6 hours post-administration, with large effect sizes observed in acute timeframes.
A clinical study was conducted in New York using ketamine for cocaine use disorder.
"And uh we're seeing some uh Let's see, I think there was also a cocaine use uh disorder study with ketamine in New York." (said at 0:42:28)
Clinical studies investigating ketamine for cocaine use disorder have been conducted in New York (such as randomized trials led by Elias Dakwar at Columbia University/New York State Psychiatric Institute). In a randomized controlled trial of 55 cocaine-dependent adults, a single subanesthetic ketamine infusion combined with mindfulness-based relapse prevention significantly promoted abstinence, reduced craving, and decreased the risk of relapse compared to active control (midazolam).
Specific genetic polymorphisms can increase activity along the kynurenine metabolic pathway.
"And that even beyond our lifestyle choices, some people have genetic polymorphisms that actually increase this so-called kynurenine pathway." (said at 0:39:50)
Published genetic and metabolomic studies confirm that single nucleotide polymorphisms (SNPs) in genes encoding enzymes of the tryptophan–kynurenine pathway (such as IDO1, IDO2, TDO2, and KMO), as well as related regulatory genes, directly modulate enzyme expression, catalytic activity, and circulating levels of kynurenine metabolites.
- supports: Identification of Genetic Markers Linked to The Activity of Indoleamine 2,3-Dioxygenase an… (Metabolites 2023) · cited 4x in the literature
"Our results identified 10 single nucleotide polymorphisms (SNPs) that were coincidently associated with both IDO and CKD ( p < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Regulation of kynurenine metabolism by blood donor genetics and biology impacts red cell h… (Blood 2024) · cited 45x in the literature
"Through a metabolite quantitative trait loci analysis, we identified polymorphisms in SLC7A5, ATXN2, and a series of rate-limiting enzymes (eg, kynurenine monooxygenase, indoleamine 2,3-dioxygenase, and tryptophan dioxygenase) in the kynurenine pathway as critical factors affecting RBC kynurenine levels." (abstract, results, passage verified)
pubmedfull study (doi)
Chronic, long-term administration of SSRIs can induce tardive dysphoria by chronically overstimulating serotonin receptors, worsening depressive symptoms after discontinuation.
"and then we we see, you know, work coming out exploring the possibility of a thing called tardive dysphoria, right? Where uh having overstimulated the serotonin receptors for decades with chronic SSRI prescription, uh now the person might be worse off when they come off of the medicine than they were in the first place." (said at 0:46:10)
The speaker accurately describes the published theoretical concept of "tardive dysphoria." Proposed by El-Mallakh and colleagues (2011), the hypothesis suggests that chronic, long-term exposure to antidepressants (such as SSRIs) may induce compensatory neuroadaptive changes leading to a treatment-resistant, prodepressant state that can leave patients experiencing persistent or worsened depressive symptoms. The speaker accurately frames this as an explored hypothesis; because it is a theoretical model based on narrative review and observational parallels rather than confirmed by randomized controlled trials, the certainty of evidence is very low.
Electrolyte deficiency during an ibogaine session contributes to its cardiac toxicity.
"And part of the cardiac toxicity of Ibogaine is not having enough electrolytes um during the session." (said at 1:03:26)
Ibogaine and its active metabolite noribogaine inherently prolong the cardiac QTc interval and predispose individuals to life-threatening ventricular arrhythmias (such as Torsades de Pointes) primarily via potent blockade of cardiac hERG potassium channels. Pre-existing or session-induced electrolyte disturbances—specifically hypokalemia and hypomagnesemia, often exacerbated by vomiting or dehydration during treatment—significantly heighten this arrhythmogenic risk. Consequently, clinical protocols and safety reviews emphasize electrolyte screening and co-administration or repletion of electrolytes (particularly magnesium) during ibogaine sessions to mitigate cardiac toxicity.
Ibogaine has an established traditional use originating in West Africa and the Gabon region.
"it has a tradition in West Africa and Gabon area that is very well established in a traditional way." (said at 1:01:09)
Anthropological and ethnobotanical literature firmly documents that ibogaine—the primary psychoactive alkaloid in the root bark of the plant *Tabernanthe iboga*—has a long-standing traditional and spiritual use in Central and West Africa, particularly within the Bwiti religious traditions of Gabon and neighbouring regions.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.